

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Table I

Percentage of Cells Expressing SA- β -Gal Cells

Cells	Φ	Doxorubicin	Taxol
MCF7	2%	24%	13%

Table II

Percentage of Cells Expressing SA- β -Gal in Patient Tissue After Herceptin Treatment

Time Elapsed	Percent
Day 0	0%
Day 2	1.5%
Day 14	26%

Table III

Expression of p53 and p21^{CIPI/WAF1} in MCF7 Cells

Treated for 3 days with Doxorubicin

Treatment	Cells stained for p53 (% Cells)	Cells stained for p21 ^{CIPI/WAF1} (% Cells)
Φ	14.43 \pm 6	10.61 \pm 4
DOX	23.93 \pm 7	50.81 \pm 6

Twenty Breast Cancer Patients Analyzed by Image Analysis Before and After Neoadjuvant Chemotherapy

	P21	P21+
Before treatment	16	4
After treatment	7	13

1. The first step is to identify the problem or question that needs to be addressed. This involves understanding the context and the specific requirements of the task.

FIG. 1A




FIG. 1B




FIG. 2A

FIG. 2A




FIG. 2B




FIG. 2C





FIG. 3A




FIG. 3B



TOP SECRET

FIG. 3C



1000X